Federal Circuit Vacates Finding That ADHD Drug Patents Are Invalid

Mealey's (November 21, 2018, 12:56 PM EST) -- WASHINGTON, D.C. — In a Nov. 20 ruling, the Federal Circuit U.S. Court of Appeals found that a Delaware federal judge’s determination of patent invalidity with regard to five patents covering an attention deficit hyperactive disorder (ADHD) drug was based upon “inadequate” fact finding (Tris Pharma Inc. v. Actavis Laboratories Inc., Nos. 2017-2557, -2559, -2560, Fed. Cir., 2018 U.S. App. LEXIS 32774)....